NCT02025114View on ClinicalTrials.gov

Selumetinib in Combination With Gefitinib in NSCLC Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 8, 2018

Study Completion Date

March 8, 2018

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

selumetinib

The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).

Trial Locations (3)

100

Department of Oncology, National Taiwan University Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

70403

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT02025114 - Selumetinib in Combination With Gefitinib in NSCLC Patients | Biotech Hunter | Biotech Hunter